MRI-guided in-bore biopsy for prostate cancer: what does the evidence say? A case series of 554 patients and a review of the current literature

Pokorny, Morgan; Kua, Boon; Esler, Rachel; Yaxley, John; Samaratunga, Hemamali; Dunglison, Nigel; Gianduzzo, Troy; Coughlin, Geoff; Holt, Ross; Laing, B.A.; Ault, Darren; Brown, Nicholas; Parkinson, R.; Thompson, Les

doi:10.1007/s00345-018-2497-y

Cited by 25 publications

(23 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reasons behind the rapid uptake of PSMA PET/CT in our institution despite the lack of robust evidence for its use are not entirely clear. One possible reason is due to the heavy research focus within both our nuclear medicine and urological departments and a willingness of clinicians to trial new imaging modalities . Despite the absence of meta‐analysis and guidelines recommending the use of PET/CT, there were early studies suggesting the benefits of using PSMA PET/CT .…”

Section: Discussionmentioning

confidence: 99%

Five‐year trends of bone scan and prostate‐specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre

et al. 2019

View full text Add to dashboard Cite

Introduction: In the last 5 years, there has been a significant focus on the use of positron emission tomography (PET) for primary and secondary staging of prostate cancer. In this study, we aim to describe the trends of use between Gallium-68 prostate-specific membrane antigen ligand (Ga-68 PSMA) PET/ computed tomography (PSMA PET/CT) and nuclear medicine bone scan (NMBS) for prostate cancer staging in the first institution in Australia to offer both modalities. Methods: We evaluated trends in prostate cancer staging/restaging imaging modalities at our facility between the time period January 2013-April 2018. Imaging logs were filtered to identify NMBS and PSMA PET/CT scans done within the time period for prostate cancer. Sub-analysis was undertaken (i) to investigate the number of patients who were imaged using both modalities, (ii) to compare the age of the patients in the NMBS group and the PSMA PET/ CT group and (iii) to compare the use of PSMA PET/CT for pre-treatment staging compared to the detection of recurrence or metastatic disease (secondary staging). Results: A total of 3144 examinations were performed in the time period reviewed, with 546 NMBS and 2598 PSMA PET/CT scans performed. In the 6 months after PSMA PET/CT was introduced, there was a 45.7% decrease in the number of NMBS performed and 95.3% decrease across the duration of the study. In the PSMA PET/CT cohort, 1569 examinations were performed for pre-treatment staging and 1029 performed for secondary staging. There was a significant difference in the proportion of PSMA PET/CT conducted for pretreatment staging compared with secondary staging when comparing the first and final 500 examinations (P < 0.05). Conclusion: After the introduction of PSMA PET/CT there was a marked decline in the use of NMBS for prostate cancer staging. This finding is of note as it occurred before there was clinical data or guidelines supporting the use of PSMA PET/CT for prostate cancer imaging.

show abstract

Section: Discussionmentioning

confidence: 99%

Five‐year trends of bone scan and prostate‐specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Суммарная продолжительность процедуры варьирует в широких пределах -от 35 до 60 мин, средняя продолжительность самой биопсии составляет 40-51 мин, а время забора гистологического материала из одного очага может занимать до 20 мин [48,[53][54][55]. Время выполнения биопсии in-bore зависит от опыта клинициста.…”

Section: ультразвуковая диагностика рака предстательной железыunclassified

The role of targeted biopsy methods in the prostate cancer diagnosis

et al. 2021

View full text Add to dashboard Cite

The current prostate cancer screening program results in unnecessary biopsies in a quarter of patients, overdiagnosis of clinically insignificant prostate cancer (ISUP 1) and overtreatment. Intoducing multiparametric magnetic resonance imaging into routine practice before biopsy allows to decrease the number of biopsies, thereby reducing the burden on clinicians and increasing the likelihood of detecting clinically significant forms of prostate cancer (ISUP >2). The objective of this literature review is to compare targeted biopsy techniques and to determine their current role in the prostate cancer diagnosis.

show abstract

“…e detection, location, and staging of prostate cancer lesions rely on conventional MRI (T2WI), but it has certain limitations in the detection of central gland (CG) cancer, so its diagnostic specificity is low [9,10]. erefore, a variety of techniques have emerged to improve the diagnostic capabilities of MRI for bone metastasis of prostate cancer, such as magnetic resonance elastic imaging (MRE), diffusion weighted imaging (DWI), and other functional MRI (fMRI) [11][12][13]. Different MRI techniques reflect different biological characteristics of prostate cancer, and the resulting images are also different.…”

Section: Introductionmentioning

confidence: 99%

ANOVA-Based Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer with Bone Metastasis and Rehabilitation Treatment

Feng

Zhu

et al. 2021

Scientific Programming

View full text Add to dashboard Cite

This study was to analyze the magnetic resonance imaging (MRI) characteristics of prostate cancer patients with bone metastasis and the difference in the rehabilitation effect of patients with different bone metastases. The MRI, diffusion weighted imaging (DWI), magnetic resonance elastic imaging (MRE), and MRI + DWI + MRE imaging were performed on 200 prostate cancer patients in the First Affiliated Hospital of Kunming Medical University hospital. The prostate-specific membrane antigen (PSMA), prostate-specific antigen (PSA), and prostate volume in patients with bone metastases were analyzed. The sensitivity, specificity, and accuracy of the four detection methods of bone metastases in prostate cancer were detected. In addition, the changes of the bone metabolism index β-special collagen sequence (β-CTX), type I procollagen amino terminal propeptide (PINP), and osteocalcin (BGP) of the patients were analyzed and compared before and after the treatment. The results showed that the levels of PSMA4 (17.35 ± 51.64 ng/mL) and PSA (15.86 ± 6.33 ng/mL) in nonbone metastatic prostate cancer patients were much lower than those of osteogenic bone metastases (668.95 ± 47.13 ng/mL and 202.15 ± 31.53 ng/mL), mixed bone metastases (637.63 ± 41.35 ng/mL and 186.45 ± 24.86 ng/mL) prostate patients. The sensitivity (96.25%), specificity (89.85%), and accuracy (98.53%) of MRI + DWI + MRE in the prostate cancer bone metastasis were obviously higher than those of MRI (86.46%, 78.31%, and 90.31%), DWI (88.11%, 82.53%, and 91.43%), and MRE (83.36%, 76.94%, and 89.76%). The levels of β-CTX (0.41 ± 0.07 ng/mL), PINP (39.04 ± 6.38 ng/mL), and BGP (17.56 ± 4.22 ng/mL) after treatment in patients with nonbone metastasis prostate cancer were greatly lower than those of osteogenic bone metastases (0.66 ± 0.08 ng/mL, 51.45 ± 7.45 ng/mL, and 33.65 ± 6.14 ng/mL) and patients with mixed bone metastases (0.75 ± 0.12 ng/mL, 53.66 ± 9.22 ng/mL, and 31.24 ± 5.73 ng/mL), showing statistically obvious differences ( P < 0.05 ). In short, the sensitivity, specificity, and accuracy of MRI + DWI + MRE in detection of prostate cancer bone metastasis were better than those of a single examination method, showing significant impacts on the rehabilitation of patients with prostate cancer bone metastasis.

show abstract

MRI-guided in-bore biopsy for prostate cancer: what does the evidence say? A case series of 554 patients and a review of the current literature

Cited by 25 publications

References 48 publications

Five‐year trends of bone scan and prostate‐specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre

Five‐year trends of bone scan and prostate‐specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre

The role of targeted biopsy methods in the prostate cancer diagnosis

ANOVA-Based Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer with Bone Metastasis and Rehabilitation Treatment

Contact Info

Product

Resources

About